US FDA extends comment deadline for feedback on opioids REMS
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has extended the deadline by which stakeholders can submit feedback on its plans to develop risk evaluation and mitigation strategies for certain opioid drugs1,2.